After further staining for galectin-3, implicated in glioma progression, as well as in membrane damage and other cellular processes, we observed a significant increase of galectin-3 staining after AF16 + TMZ compared to controls (p = 0.029, Fig. 3c). The gene discussed is LGALS3; the disease is central nervous system cancer.